# US 2010/0303915 A1 · Therapeutic opthalmic emulsions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0303915 A1
- Document ID: US20100303915A1
- Status: Published application
- Kind: A1
- Application number: 12/476,547
- Filed: 2009-06-02
- Published: 2010-12-02
- Earliest claimed: 2009-06-02
- Assignees: Abbott Medical Optics Inc.
- Inventors: Zhi-Jian Yu
- Web page: https://patentgrep.com/patent/US20100303915A1

## CPC

- A61K 9/0048: {Eye, e.g. artificial tears}
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are non-irritating ophthalmic emulsion compositions useful for treating ocular disorders including dry eye and related methods. More specifically, the ophthalmic compositions disclosed herein combine a high HLB surfactant and a low HLB surfactant together with a plant-derived triglyceride having non-polar aliphatic side chains to form a therapeutic non-irritating eye drop.

## Claims

### Claim 1

A method for increasing therapeutic agent delivery efficacy of an ophthalmic emulsion comprising:
selecting at least one ophthalmically acceptable oil wherein said oil comprises only aliphatic side chains free of polar pendent groups,
selecting a hydrophobic therapeutic agent for topical delivery into the eye,
selecting a hydrophobic non-co-block surfactant having an HLB value less than 8,
selecting a hydrophilic surfactant having an HLB value greater than 8,
admixing said oil, said hydrophobic therapeutic oil, said hydrophobic surfactant and said hydrophilic surfactant with a sufficient amount of water such that a stable emulsion forms having an average particle size less than 1 μm in diameter and wherein said emulsion is not irritating to the eye when applied topically to said eye and wherein the hydrophobic therapeutic agent is delivered more efficiently to the eye compared with an ophthalmic emulsion having one surfactant or a surfactant pair where both surfactants have an HLB value greater than 8.

### Claim 2 (depends on 1)

The method for increasing therapeutic agent delivery efficacy of an ophthalmic emulsion according to claim 1 wherein said hydrophilic surfactant has an HLB between 8.0 and 25.0 and said hydrophobic non-co-block surfactant has an HLB between 7.9 and 1.0.

### Claim 3 (depends on 1)

The method for increasing therapeutic agent delivery efficacy of an ophthalmic emulsion according to claim 1 wherein said hydrophilic surfactant content relative to said hydrophobic non-co-block surfactant content is a ratio of 10.0 to 4.9.

### Claim 4 (depends on 1)

The method for increasing therapeutic agent delivery efficacy of an ophthalmic emulsion according to claim 1 wherein said hydrophilic surfactant content relative to said hydrophobic non-co-block surfactant content is a ratio of 14.5 to 4.9.

### Claim 5 (depends on 1)

The method for increasing therapeutic agent delivery efficacy of an ophthalmic emulsion according to claim 1 wherein said hydrophilic surfactant content relative to said hydrophobic non-co-block surfactant content is a ratio of 10.0 to 2.0.

### Claim 6 (depends on 1)

The method for increasing therapeutic agent delivery efficacy of an ophthalmic emulsion according to claim 1 wherein said hydrophilic surfactant content relative to said hydrophobic non-co-block surfactant content is a ratio of 14.5 to 2.0.

### Claim 7 (depends on 1)

The method for increasing therapeutic agent delivery efficacy of an ophthalmic emulsion according to claim 1 wherein said hydrophilic surfactant is Lumulse® GRH 40 or Lumulse® GRH 25 and said hydrophobic non-co-block surfactant surfactant is Brij 72 or Brij 93.

### Claim 8 (depends on 1)

The method for increasing therapeutic agent delivery efficacy of an ophthalmic emulsion according to claim 1 wherein said at least one oil having non-polar alkyl side chains is selected from the group consisting of sesame oil, cherry kernel oil, pumpkin seed oil, hemp seed oil, flax seed oil, perilla seed oil, soybean oil, olive oil, canola oil, corn oil and blackcurrant seed oil.

### Claim 9 (depends on 1)

The method for increasing therapeutic agent delivery efficacy of an ophthalmic emulsion according to claim 1 wherein said at least one oil having non-polar alkyl side chains is from cold water fish selected from the group consisting of cod liver oil, salmon oil, anchovy oil and tuna oil.

### Claim 10 (depends on 1)

The method for increasing therapeutic agent delivery efficacy of an ophthalmic emulsion according to claim 1 further comprising excipients selected from the group consisting of buffers, microbicides, demulcents, viscosity modifying agents, metal salts, emulsion stabilizers and therapeutic agents.

### Claim 11

An ophthalmic oil-in-water emulsion composition comprising at least one oil other than castor oil or mineral oil wherein said oil comprises aliphatic or alkyl side chains free of polar pendent groups, a hydrophilic surfactant having an HLB value greater than 8, hydrophobic non-co-block surfactant having an HLB value less than 8, water; and wherein said oil-in-water emulsion composition has an average particle size less than 1 μm in diameter.

### Claim 12 (depends on 11)

The ophthalmic oil-in-water emulsion composition according to claim 11 wherein said hydrophilic surfactant has an HLB between 8.0 and 25.0 and said hydrophobic non-co-block surfactant has an HLB between 7.9 and 1.0.

### Claim 13 (depends on 11)

The ophthalmic oil-in-water emulsion composition according to claim 11 wherein said hydrophilic surfactant content relative to said hydrophobic non-co-block surfactant content is a ratio of 10.0 to 4.9.

### Claim 14 (depends on 11)

The ophthalmic oil-in-water emulsion composition according to claim 11 wherein said hydrophilic surfactant content relative to said hydrophobic non-co-block surfactant content is a ratio of 14.5 to 4.9.

### Claim 15 (depends on 11)

The ophthalmic oil-in-water emulsion composition according to claim 11 wherein said hydrophilic surfactant content relative to said hydrophobic non-co-block surfactant content is a ratio of 10.0 to 2.0.

### Claim 16 (depends on 11)

The ophthalmic oil-in-water emulsion composition according to claim 11 wherein said hydrophilic surfactant content relative to said hydrophobic non-co-block surfactant content is a ratio of 14.5 to 2.0.

### Claim 17 (depends on 11)

The ophthalmic oil-in-water emulsion composition according to claim 11 wherein said hydrophilic surfactant is Lumulse® GRH 40 or Lumulse® GRH 25 and said hydrophobic non-co-block surfactant surfactant is Brij 72 or Brij 93.

### Claim 18 (depends on 11)

The ophthalmic oil-in-water emulsion composition according to claim 11 wherein said at least one oil having non-polar alkyl side chains is selected from the group consisting of sesame oil, cherry kernel oil, pumpkin seed oil, hemp seed oil, flax seed oil, perilla seed oil, soybean oil, olive oil, canola oil, corn oil and blackcurrant seed oil.

### Claim 19 (depends on 11)

The ophthalmic oil-in-water emulsion composition according to claim 11 wherein said at least one oil having non-polar alkyl side chains is from cold water fish selected from the group consisting of cod liver oil, salmon oil, anchovy oil and tuna oil.

### Claim 20 (depends on 11)

The ophthalmic oil-in-water emulsion composition according to claim 11 further comprising excipients selected from the group consisting of buffers, microbicides, demulcents, viscosity modifying agents, metal salts, emulsion stabilizers and therapeutic agents.

### Claim 21

An ophthalmic oil-in-water emulsion composition comprising an average particle size less than 1 μm, least one oil other than castor oil or mineral oil wherein said oil comprises aliphatic or alkyl side chains free of polar pendent groups, a hydrophilic surfactant having an HLB value between approximately 10 and 14 and a hydrophobic non-co-block surfactant having an HLB value between approximately 4 and 6.

### Claim 22

An ophthalmic oil-in-water emulsion composition comprising an average particle size less than 0.6 μm and wherein said oil-in-water emulsion consists essentially of water, at least one oil other than castor oil or mineral oil wherein said oil comprises aliphatic or alkyl side chains free of polar pendent groups, a hydrophilic surfactant having an HLB value between approximately 12 and 14 and a hydrophobic non-co-block surfactant having an HLB value between approximately 4 and 5.

### Claim 23

An ophthalmic oil-in-water emulsion composition comprising an average particle size less than 0.6 μm and wherein said oil-in-water emulsion consists essentially of water, at least one oil other than castor oil or mineral oil wherein said oil comprises aliphatic or alkyl side chains free of polar pendent groups and a hydrophilic surfactant having an HLB value between approximately 10 and 11, a hydrophobic non-co-block surfactant having an HLB value between approximately 4 and 5.

### Claim 24

An ophthalmic oil-in-water emulsion composition comprising an average particle size less than 0.6 μm and wherein said oil-in-water emulsion consists essentially of water, sesame oil and a hydrophilic surfactant consisting of Lumulse® GRH 25 and a hydrophobic non-co-block surfactant consisting of Brij 93.

### Claim 25

An ophthalmic oil-in-water emulsion composition comprising an average particle size less than 0.6 μm and consists essentially of sesame oil, a hydrophilic surfactant having consisting of Lumulse® GRH 40 or Lumulse® GRH 25, a hydrophobic non-co-block surfactant consisting of Brij 93 or Brij 72 and wherein in said ophthalmic composition further comprises an amount of cyclosporine A effective to relieve dry eye symptoms.
